Sabby Management’s AEON Biopharma AEON Stock Holding History

Sabby Management’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-449,687	Closed	-$261K	–	44
2025 Q1	$261K	Buy	+449,687	New	+$3.2M	0.77%	24

Other funds holding AEON

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

DCM

Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sabby Management's AEON Position: Q2 2025 in Review

Sabby Management sold out of AEON Biopharma (AEON) in Q2 2025, closing a stake of 449,687 shares — an estimated $261K sold.

Sabby Management first reported a position in AEON in Q1 2025 and held it in 1 quarter. The position peaked at $261K in Q1 2025. 18 funds tracked by Wall St. Rank hold AEON as of Q2 2025.

Sabby Management reported no remaining AEON Biopharma position as of Q2 2025 after selling out during the quarter.
Sabby Management sold 449,687 AEON Biopharma shares in Q2 2025, an estimated $261K.
Sabby Management first reported a position in AEON Biopharma in Q1 2025 and held it in 1 quarter.
Sabby Management's AEON Biopharma position peaked at $261K in Q1 2025.
18 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2025.

Based on Sabby Management's 13F filing for Q2 2025, filed 14 Aug 2025.